Polygenic Risk Score for Optimizing Primary Prevention in Intermediate-Risk Populations

The goal of this clinical trial is to determine whether incorporating a polygenic risk score (PRS) can optimize primary cardiovascular disease prevention in individuals with intermediate cardiovascular risk. The main questions it aims to answer are: * Can a polygenic risk score improve risk stratification in intermediate-risk individuals? * Does disclosing polygenic risk information to patients and physicians lead to better preventive interventions (e.g., statin use, lifestyle changes)? Researchers will compare outcomes in participants with PRS disclosure versus standard risk assessment to see if PRS-guided prevention leads to improved cardiovascular risk management. Participants will: * Undergo baseline cardiovascular risk assessment * Provide a blood sample for PRS calculation * Complete follow-up visits for lifestyle counseling, medication review, and risk reassessment

NCT Number	NCT07039123
Lead Sponsor	University of Bern
Conditions	Primary Prevention of Cardiovascular Disease
Enrollment	205 participants
Start Date	2025-07-08
Primary Completion	2027-11-08 (estimated)
Study Completion	2027-11-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-30